AU2011287193B2 - Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof - Google Patents

Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof Download PDF

Info

Publication number
AU2011287193B2
AU2011287193B2 AU2011287193A AU2011287193A AU2011287193B2 AU 2011287193 B2 AU2011287193 B2 AU 2011287193B2 AU 2011287193 A AU2011287193 A AU 2011287193A AU 2011287193 A AU2011287193 A AU 2011287193A AU 2011287193 B2 AU2011287193 B2 AU 2011287193B2
Authority
AU
Australia
Prior art keywords
hmgb1
hmgbl
fecal
protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011287193A
Other languages
English (en)
Other versions
AU2011287193A1 (en
Inventor
Salvatore Cucchiara
Laura Stronati
Roberta Vitali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMG Italia SRL
Original Assignee
DMG Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DMG Italia SRL filed Critical DMG Italia SRL
Publication of AU2011287193A1 publication Critical patent/AU2011287193A1/en
Application granted granted Critical
Publication of AU2011287193B2 publication Critical patent/AU2011287193B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2011287193A 2010-08-05 2011-08-01 Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof Ceased AU2011287193B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
ITRM2010A000442 2010-08-05
PCT/IT2011/000276 WO2012017466A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof

Publications (2)

Publication Number Publication Date
AU2011287193A1 AU2011287193A1 (en) 2013-06-13
AU2011287193B2 true AU2011287193B2 (en) 2015-08-13

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011287193A Ceased AU2011287193B2 (en) 2010-08-05 2011-08-01 Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof

Country Status (14)

Country Link
US (1) US20130137123A1 (enExample)
EP (1) EP2601525A1 (enExample)
JP (1) JP2013534313A (enExample)
CN (1) CN103069276A (enExample)
AU (1) AU2011287193B2 (enExample)
BR (1) BR112013002145A2 (enExample)
CA (1) CA2807107C (enExample)
CL (1) CL2013000223A1 (enExample)
EA (1) EA201390197A1 (enExample)
IL (1) IL223845A (enExample)
IT (1) IT1406051B1 (enExample)
MX (1) MX2013001327A (enExample)
PE (1) PE20131062A1 (enExample)
WO (1) WO2012017466A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
PT2968443T (pt) 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
ES2977537T3 (es) 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2018089693A2 (en) * 2016-11-09 2018-05-17 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
DK3622082T3 (da) 2017-05-12 2023-06-12 Evonik Operations Gmbh Fremgangsmåde til påvisning af c. perfringens-inducerede sygdomme i en fugleflok
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3092472A1 (en) * 2018-03-02 2019-09-06 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
ES2938227T3 (es) 2018-12-14 2023-04-05 Evonik Operations Gmbh Método in vitro de detección de disbiosis intestinal aviar
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
CN115279782A (zh) 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
IL294680A (en) 2020-01-15 2022-09-01 Janssen Biotech Inc Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
IL302996B2 (en) 2020-11-20 2025-04-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009749A1 (en) * 1996-07-17 2002-01-24 Shoichi Ozaki Diagnostic drugs for autoimmune diseases
WO2009114756A2 (en) * 2008-03-14 2009-09-17 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
EP1601969A2 (en) * 2003-03-08 2005-12-07 Auvation Ltd Markers for colorectal cancer
WO2007001422A2 (en) * 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
WO2008075788A1 (ja) * 2006-12-20 2008-06-26 Shino-Test Corporation ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬
EP2185936A4 (en) * 2007-08-02 2010-08-04 Iss Immune System Stimulation DIAGNOSIS, STADIFICATION AND SURVEILLANCE OF INFLAMMATORY ABDOMINAL DISEASE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009749A1 (en) * 1996-07-17 2002-01-24 Shoichi Ozaki Diagnostic drugs for autoimmune diseases
WO2009114756A2 (en) * 2008-03-14 2009-09-17 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVE, S.H. et al. Journal of Leukocyte Biology, 2009, vol. 86, pages 633-643. *

Also Published As

Publication number Publication date
PE20131062A1 (es) 2013-10-16
IT1406051B1 (it) 2014-02-06
IL223845A (en) 2016-06-30
US20130137123A1 (en) 2013-05-30
CA2807107A1 (en) 2012-02-09
WO2012017466A8 (en) 2013-07-11
CN103069276A (zh) 2013-04-24
BR112013002145A2 (pt) 2016-05-24
MX2013001327A (es) 2013-03-08
EP2601525A1 (en) 2013-06-12
CA2807107C (en) 2017-01-03
JP2013534313A (ja) 2013-09-02
ITRM20100442A1 (it) 2012-02-06
EA201390197A1 (ru) 2013-06-28
AU2011287193A1 (en) 2013-06-13
CL2013000223A1 (es) 2014-03-28
WO2012017466A1 (en) 2012-02-09

Similar Documents

Publication Publication Date Title
AU2011287193B2 (en) Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
Zollner et al. Faecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2—a comparative study
Leach et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease
Kaiser et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome
Costa et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation
D'angelo et al. Calprotectin in daily practice: where do we stand in 2017?
Carroccio et al. Fecal assays detect hypersensitivity to cow's milk protein and gluten in adults with irritable bowel syndrome
JP2019194600A (ja) 過敏性腸症候群を診断するための経路特異的マーカー
Ministro et al. Fecal biomarkers in inflammatory bowel disease: how, when and why?
Rogler et al. Clinical utility of biomarkers in IBD
KR20100063052A (ko) 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법
Klimczak et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity
Turkay et al. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update
Al Biochemical significance of cystatin-C and high-sensitive CRP in patients with acute coronary syndrome; any clinical correlation with diagnosis and ejection fraction
Ge et al. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis
Vaiopoulou et al. Current advantages in the application of proteomics in inflammatory bowel disease
CA2800371A1 (en) Methods of renal cancer detection
Katsumata et al. Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases
Kaila et al. The Anti‐Saccharomyces Cerevisiae Antibody Assay in a Province‐Wide Practice: Accurate in Identifying Cases of Crohn’s Disease and Predicting Inflammatory Disease
Pham et al. Subclinical intestinal inflammation in siblings of children with Crohn’s disease
Waluga Biomarkers of irritable bowel syndrome
CN114270191B (zh) 炎症性肠病诊断方法、诊断探针和诊断试剂盒
US20220214357A1 (en) Method of determining the probability of inflammatory bowel disease in a subject being ulcerative colitis or crohn's disease
JP6158825B2 (ja) テネイシンｃおよび関節リウマチにおけるその使用
KR20130136964A (ko) 창자 감염성 병태의 생물학적 마커로서 hmgb1의 용도, 대변 샘플에서 그의 검출을 위한 비침습적 방법 및 키트

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 05 APR 2013 .

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired